Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Drug Discovery
Intellectual Property
R&D Pipeline
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Nutra Pharma, through its subsidiary ReceptoPharm, is taking on some of the world's most difficult diseases including Multiple Sclerosis, HIV/AIDS, Adrenomyeloneuropathy, and Herpes.

RPI-MN: Modified Cobra Venom for Viral Diseases

Herpes is a group of related diseases marked by the development of blisterlike sores on the skin or mucous membranes of the body.
Human Immunodeficiency Virus (HIV / AIDS)
The Human Immunodeficiency Virus (HIV) is the virus that causes AIDS, a debilitating and deadly disease of the human immune system. The World Health Organization (WHO) estimates that 20 million people have died from AIDS since 1981. It is estimated that at the end of 2001, there were more than 40 million people worldwide infected with HIV and living with the virus or AIDS.

RPI-78M: Modified Alpha Cobratoxin for Autoimmune Diseases

Adrenomyeloneuropathy (AMN)
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that effects approximately 20,000 people globally. Its symptoms are very similar to those of progressive Multiple Sclerosis (MS).
Additional Information: AMNHelp
Multiple Sclerosis (MS)
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system causing muscular weakness, loss of coordination, and speech and visual disturbances.
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
February 16, 2016
Nutra Pharma Announces Management Expansion and Business Updates

December 30, 2015
Nutra Pharma Letter to Shareholders

December 16, 2015
Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics